Rondo Therapeutics
Rondo Therapeutics is a clinical-stage biotechnology company based in Hayward, California, developing immune-cell engaging bispecific antibodies designed to treat solid tumors by unleashing the immune system while maximizing efficacy and minimizing side effects. Founded in 2019 by Shelley Force Aldred and Nathan Trinklein, its pipeline includes RNDO-564 (Phase 1 for bladder cancer) plus programs targeting ovarian, endometrial, and renal cancers, backed by a Series A led by Canaan and Red Tree Venture Capital and a collaboration with Eli Lilly. Rondo publishes a corporate and pipeline website but exposes no public developer program, API, or machine-readable API surface; it was surfaced as a portfolio company of canaan-partners and added to the API Evangelist network for enrichment.
Rondo Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Therapeutics, Oncology, and Antibodies.
Kin Score
Resources
Commercial 2
Pricing, plans, and the legal terms of use
Company 2
The organization behind the API